Microparticles as vaccine adjuvants and delivery systems

References

• Ramon G. Sur la toxine et surranatoxine diphtheriques. Ann. Inst. Pasteur38,1 (1924).
   Google Scholar
• Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. In: Vaccine Design: the Subunit anti Acljuvant Appmach. Powell MF, Newman MJ, (Eds). Plenum Press, NY, USA, 141–228 (1995).
   Google Scholar
• Gupta RK. Aluminum compounds as vaccine adjuvants. Acv Drug- Del Rev 32,155–172 (1998).
   PubMed Web of Science ®Google Scholar
• Relyveld EH, Bizzini B, Gupta RK. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine16(9-10), 1016–1023 (1998).
   PubMed Web of Science ®Google Scholar
• Gupta RK, Chang AC, Griffin P et al. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing MC-labeled tetanus toxoid. Vaccine 14(15), 1412–1416 (1996).
   PubMed Web of Science ®Google Scholar
• Ulanova M, Tarkowski A, Hahn-Zoric M et al. The common vaccine adjuvant aluminum hydroxide upregulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. human. 69(2), 1151–1159 (2001).
   Google Scholar
• Shi Y, HogenEsch H, Regnier FE et al. Detoxification of endotoxin by aluminum hydroxide adjuvant. Vaccine 19(13-14), 1747–1752 (2001).
   PubMed Web of Science ®Google Scholar
• Edelman R. Adjuvants for the future. In: New Generation Vaccines. Levine MM, Woodrow GC, Kaper JB, Cobon GS (Eds). Marcel Dekker, Inc., NY, USA, 173–192 (1997).
   Google Scholar
• Zinkernagel RM, Ehl S, Aichele P et al Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev. 156,199–209. (1997).
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring- Harbor Symposium on Quantitative Biology54\(Pt 1) Ch 1–13 (1989).
   Google Scholar
• Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Ce1191 (3), 295–298 (1997).
   Google Scholar
• Fearon DT Seeking wisdom in innate immunity. Nature 388 (6640), 323–324 (1997).
   Google Scholar
• Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 272(5258), 50–53 (1996).
   PubMed Web of Science ®Google Scholar
• Yip HC, Karulin AY, Tary-Lehmann M et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. Immunol 162(7), 3942–3949 (1999).
   Google Scholar
• Gustafson GL, Rhodes MJ. Bacterial cell wall products as adjuvants: early interferon y as a marker for adjuvants that enhance protective immunity. Res. Immunol 143(5), 483–488, discussion 573–574 (1992).
   Google Scholar
• Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant: Past experiences and new directions. Pharm. Biotechnol 6, 495–524 (1995).
   PubMedGoogle Scholar
• Ulrich JT. MPLr immunostimulant: adjuvant formulations. In: Vaccine Adjuvants: Preparation Methods and Research Protocols. O'Hagan DT (Ed.). Humana Press, Inc., NJ, USA, 273–282 (2000).
   Google Scholar
• Wheeler AW, Marshall JS, Ulrich JT. A Thl-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. int. Arch. Allergy Immund 126(2), 135–139 (2001).
   Google Scholar
• Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. I Immunol 147(6), 1759–1764 (1991).
   PubMed Web of Science ®Google Scholar
• Tokunaga T, Yamamoto H, Shimada S et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. I Nat! Cancer Inst. 72(4), 955–962 (1984).
   Google Scholar
• Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522), 6546–6549 (1995).
   Web of Science ®Google Scholar
• Bird AP CpG islands as gene markers in the vertebrate nucleus. 7iends Genet. 3,342–347 (1987).
   Google Scholar
• Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Natum 408(6813), 740–745 (2000).
   PubMed Web of Science ®Google Scholar
• Sparwasser T, Koch ES, Vabulas RM et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur Immunol. 28(6), 2045–2054 (1998).
   Google Scholar
• Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 17(1), 19–25 (1999).
   PubMed Web of Science ®Google Scholar
• Broide D, Schwarz e Tighe, J. H et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation and airway hyperresponsiveness in mice. I hrimunol 161(12), 7054–7062 (1998).
   Google Scholar
• Kensil CR. Saponins as vaccine adjuvants. On. Rev Ther Drug Carrier Syst. 13(1-2), 1–55 (1996).
   PubMed Web of Science ®Google Scholar
• Glaueri AM, Dingle JT, Lucy JA. Action of saponins on biological membranes. Nature 196,953 (1962).
   Google Scholar
• Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Exp. Opin. Invest. Drugs 7(9), 1475–1482 (1998).
   Google Scholar
• Heath AW. Cytokines as immunological adjuvants. Phann Biotechnol. 6,645–658 (1995).
   PubMedGoogle Scholar
• Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J SUrg, Oncol. 68(2), 122–138 (1998).
   Google Scholar
• Pettit DK, Lawter JR, Huang WJ et al. Characterization of poly(glycolide-co-D,L-lactide)/poly(D,L-lactide) miul_bpheres for controlled release of GM-CSE Pharm. Res. 14(10), 1422–1430 (1997).
   Google Scholar
• Egilmez NK, Jong YS, Sabel MS et al. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 60(14), 3832–3837 (2000).
   Google Scholar
• Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. hnmunol. Method 95 (2), 157–168 (1986).
   Google Scholar
• Lindblad EB. Freund's Adjuvants. In: Vaccine Adjuvants: Preparation methods and msemrh protocols. O'Hagan D, (Ed.). Humana Press, NJ, USA,49–64 (2000).
   Google Scholar
• Ott G, Barchfeld GL, Chernoff D et al MF59: Design and evaluation of a safe and potent adjuvant for human vaccines. In: Vaccine Design: the Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds). Plenum Press, NY, USA, 277–296 (1995).
   Google Scholar
• Cataldo DM, Van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 15(16), 1710–1715 (1997).
   Google Scholar
• Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 14 (6), 478–484 (1996).
   Google Scholar
• O'Hagan DT, Ott GS, Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mal Med. Today 3, 69–75 (1997).
   Google Scholar
• Traquina P, Morandi M, Contorni M et al. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. I Infect. Dis. 174(6), 1168–1175 (1996).
   Google Scholar
• Heineman TC, Clements-Mann ML, Poland GA et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17(22), 2769–2778 (1999).
   Google Scholar
• Menegon T, Baldo V, Bonello C et al. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur j Epidemiol. 15(6), 573–576 (1999).
   Google Scholar
• De Donato S, Granoff D, Minutello M et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17 (23–24), 3094–3101 (1999).
   Google Scholar
• Cunningham CK, Wara DW, Kang M et al. Safety of 2 recombinant human immunodeficiency virus Type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin. Infect. Dis. 32(5), 801–807 (2001).
   Google Scholar
• Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. AIDS Vaccine Evaluation Group 022 Protocol Team. I Infect. Dis. 183(4), 563–570 (2001). Biodegradable and biocompatible poly(IDL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 59(9), 2978–2986 (1991).
   Google Scholar
• Cherpelis S, Srivastava I, Gettie A et al. DNA vaccination with the human immunodeficiency virus Type 1 SF1628V2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. Viral. 75(3), 1547–1550 (2001).
   Google Scholar
• Alving CR. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim Biophys Acta. 1113(3-4), 307–322 (1992).
   Google Scholar
• Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Todayll (3), 89–97 (1990).
   Google Scholar
• Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15(11), 1209–1213 (1997).
   PubMed Web of Science ®Google Scholar
• Barr IG, Sjolander A, Cox JC. ISCOMs and other saponin-based adjuvants. Adv Drug Del. Rev 32,247–271 (1998).
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Baars M, van Beek R et al Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and ISCOM vaccines. 78(Pt 4), 757–765 (1997).
   Google Scholar
• Ennis FA, Cruz J, Jameson J et al. Augmentation of human influenza A virus-specific cytotoxic T-lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS) . Vimlogy 259 (2), 256–261 (1999).
   PubMed Web of Science ®Google Scholar
• Soltysik S, Wu JY, Recchia J et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 13(15), 1403–1410 (1995).
   Google Scholar
• Lovgren-Bengtsson K, Morein B. The ISCONFm Technology. In: !!!!!!Vaccine Adjuvants: Pmparation methods and msearrh protocols. OHagan D (Ed.). Humana Press Totowa, NJ, USA, 239–258 (2000).
   Google Scholar
• OHagan DT Microparticles as oral vaccines. In: Novel Deliver), Systems for Oral Vaccine. OHagan DT (Ed.). CRC Press Inc., FL, USA 175–205 (1994).
   Google Scholar
• Kovacsovics-Bankowski M, Clark K, Benacerraf B et al. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Pmc. Nail Acad. Li. USA 90(11), 4942–4946 (1993).
   Google Scholar
• Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Grit. Rev The Drug Carrier Syst. 12(1), 1–99 (1995).
   PubMed Web of Science ®Google Scholar
• Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 16(2), 153–157 (1998). Published erratum appears in Nat. Biotechnol. 16(5), 478 (1998).
   Google Scholar
• Eldridge JH, Staas JK, Meulbroek JA et al. Biodegradable and biocompatible poly(DLlactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxinneutralizing antibodies. Infect. Immun. 59(9), 2978–2986 (1991).
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Rahman D, McGee JP et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology73(2), 239–242 (1991).
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Jeffery H, Roberts MJ et al. Controlled release microparticles for vaccine development. Vaccine 9(10), 768–771 (1991).
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccinell(9), 965–969 (1993).
   Google Scholar
• Maloy KJ, Donachie AM, OHagan DT et al. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunol 81(4), 661–667 (1994).
   PubMed Web of Science ®Google Scholar
• Moore A, McGuirk P, Adams S et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T-lymphocytes and CD4+ Thl cells. Vaccine 13(18), 1741–1749 (1995).
   Google Scholar
• Nixon DF, Hioe C, Chen PD et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T-cell activity. Vaccine 14(16), 1523–1530 (1996).
   PubMed Web of Science ®Google Scholar
• Kanke M, Sniecinski I, DeLuca PP Interaction of microspheres with blood constituents: I. Uptake of polystyrene spheres by monocytes and granulocytes and effect on immune responsiveness of lymphocytes. .1. Parente Sci Technol 37 (6), 210–217 (1983).
   Google Scholar
• Tabata Y, Ilcada Y. Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and co-polymers. .1. Biomed Mater Res. 22 (10), 837–858 (1988).
   Google Scholar
• Tabata Y, Ikada Y. Phagocytosis of polymer microspheres by macrophages. Adv. Polymer Sci. 94,107–141 (1990).
   Web of Science ®Google Scholar
• Randolph GJ, Inaba K, Robbiani DF et al. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity11(6), 753–761 (1999).
   PubMed Web of Science ®Google Scholar
• Lutsiak ME, Robinson DR, Coester C et al. Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in Wm. Pharm. Res. 19(10), 1480–1487 (2002).
   PubMed Web of Science ®Google Scholar
• Newman KD, Elamanchili P, Kwon GS et al. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. I Domed Mater. Res. 60(3), 480–486 (2002).
   Google Scholar
• O'Hagan DT, Ugozzoli M, Barackman J et al. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. Vaccine 18(17), 1793–1801 (2000).
   Google Scholar
• Vordermeier HM, Coombes AG, Jenkins P et al. Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M tuberulosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vaccine 13 (16), 1576–1582 (1995).
   Google Scholar
• Kazzaz J, Neidleman J, Singh M et al. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T-lymphocytes against recombinant p55 gag from HIV-1.j Control Release 67(2–3), 347–356 (2000).
   Google Scholar
• Jung T, Kamm W, Breitenbach A et al. Tetanus toxoid loaded nanoparticles from sulfobutylated poly (vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm. Res. 18(3), 352–360 (2001).
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 11(9), 965–969 (1993).
   PubMed Web of Science ®Google Scholar
• Seder RA, Gurunathan S. DNA vaccines —designer vaccines for the 21st century. N. Engl. Med 341(4), 277–278 (1999).
   Google Scholar
• Wang R, Doolan DL, Le TP et al. Induction of antigen-specific cytotoxic T-lymphocytes in humans by a malaria DNA vaccine. Science 282(5388), 476–480 (1998).
   PubMed Web of Science ®Google Scholar
• Calarota S, Bratt G, Nordlund S et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351(9112), 1320–1325 (1998).
   Google Scholar
• Schneider J, Gilbert SC, Blanchard TJ et al. Enhanced immunogenicity for CD8+ T-cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4(4), 397–402 (1998).
   Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature408(6812), 605–609 (2000).
   PubMed Web of Science ®Google Scholar
• Amara RR, Villinger F, Altman JD et al. Control of a mucosal challenge and prevention of AIDS by a multi-protein DNA/MVA vaccine. Sc1ence292(5514), 69–74. (2001).
   Google Scholar
• Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med 4(3), 365–368 (1998).
   PubMed Web of Science ®Google Scholar
• Singh M, Briones M, Ott G et al. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl Acad. Sc]. USA 97(2), 811–816 (2000).
   Google Scholar
• Walter E, Moelling K, Pavlovic J al Microencapsulation of DNA using poly(DL-lactide-co-glycolide): stability issues and release characteristics. 61,361–374 (1999).
   Google Scholar
• Ando S, Putnam D, Pack DW al PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. j Phatm. Sci. 88(1), 126–130 (1999).
   Google Scholar
• Tinsley-Bown AM, Fretwell R, Dowsett AB et al. Formulation of poly(D,L-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery j Control Release 66(2–3), 229–241 (2000).
   Google Scholar
• Briones M, Singh M, Ugozzoli M al The preparation, characterization and evaluation of cationic microparticles for DNA vaccine delivery. Phatm. Res. 18(5), 709–711 (2001).
   PubMed Web of Science ®Google Scholar
• O'Hagan D, Singh M, Ugozzoli M al Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. j Vim]. 75(19), 9037–9043 (2001).90Denis-Mize KS, Dupuis M, MacKichan ML et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 7(24), 2105–2112 (2000).
   Google Scholar
• Denis-Mize KS, Dupuis M, MacKichan ML et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 7(24), 2105–2112 (2000).
   Google Scholar
• Ott G, Singh M, Kazzaz J et al. A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. j Control. Release 79 (1–3), 1–5 (2002).
   Google Scholar
• Singh M, Ott G, Kazzaz J et al. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm. Res. 18(10), 1476–1479 (2001).
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. j Pharm. Pharmacol 39(9), 698–704 (1987).
   Web of Science ®Google Scholar
• Puri N, Sinko PJ. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation. j Control. Release 69(1), 69–80 (2000).
   Google Scholar
• Cleland JL, Barron L, Daugherty A et al Development of a single-shot subunit vaccine for HIV-1.3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. Pharm. Sci. 85(12), 1350–1357 (1997).
   Google Scholar
• Singh M, Li XM, Wang H et al Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect. Immun. 65(5), 1716–1721 (1997).
   PubMed Web of Science ®Google Scholar
• Singh M, Carlson JR, Briones M et al A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 16(19), 1822–1827 (1998).
   Google Scholar
• O'Hagan DT, Ugozzoli M, Barackman J etal. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1, Vaccine 18(17), 1793–1801 (2000).
   Google Scholar
• O'Hagan DT, Singh M, Gupta RK. Poly (lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv. Drug-Del. Rev. 32,225–246 (1998).
   PubMed Web of Science ®Google Scholar
• Schwendeman SP, Costantino HR, Gupta RK et al. Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. Proc. Natl Acad. Sci. USA 92(24), 11234–11238 (1995).
   Google Scholar
• Xing DK, Crane DT, Bolgiano B, Corbel MJ, Jones C, Sesardic D. Physicochemical and immunological studies on the stability of free and microsphere-encapsulated tetanus toxoid in vitro. Vaccine 14(13), 1205–1213 (1996).
   PubMed Web of Science ®Google Scholar
• Johansen P, Gander B, Merkle HP et al. Ambiguities in the preclinical quality assessment of microparticulate vaccines. Trends Biotechnol 18(5), 203–211 (2000).
   PubMed Web of Science ®Google Scholar
• Sasiak AB, Bolgiano B, Crane DT et al. Comparison of in vitro and in vivo methods to study stability of PLGA microencapsulated tetanus toxoid vaccines. Vaccine 19(7-8), 694–705 (2001).
   Web of Science ®Google Scholar
• Boehm G, Peyre M, Sesardic D et al. On technological and immunological benefits of multivalent single-injection microsphere vaccines. Pharm. Res. 19(9), 1330–1336 (2002).
   PubMed Web of Science ®Google Scholar
• Men Y, Thomasin C, Merkle HP et al. A single administration of tetanus toxoid in biodegradable microspheres elicits T-cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine 13 (7), 683–689 (1995).
   PubMed Web of Science ®Google Scholar
• Preis I, Langer RS. A single-step immunization by sustained antigen release. Immunol Method 28(1-2), 193–197 (1979).
   PubMed Web of Science ®Google Scholar
• McGee JP, Davis SS, O'Hagan D. The immunogenicity of a model protein entrapped in poly (lactide-co-glycolide) microparticles prepared by a novel phase separation technique. j Control. Release 31, 55–60 (1994).
   Google Scholar
• Johansen P, Estevez F, Zurbriggen R et al. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine 19(9-10), 1047–1054 (2000).
   PubMed Web of Science ®Google Scholar
• Newman MJ, Balusubramanian M, Todd CW Development of adjuvant-active nonionic block co-polymers. Adv. Drug Del. Rev. 32,199–223 (1998).
   PubMed Web of Science ®Google Scholar
• Payne LG, Jenkins SA, Woods AL et al. Poly [di (carboxylatophenoxy) phosphazend (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 16(1), 92–98 (1998).
   PubMed Web of Science ®Google Scholar
• Valenzuela P, Medina A, Rutter WJ et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298(5872), 347–350 (1982).
   PubMed Web of Science ®Google Scholar
• Schirmbeck R, Bohm W, Ando K etal. Nucleic-acid vaccination primes hepatitis-B virus surface antigen-specific cytotoxic T-lymphocytes in nonresponder mice. j Viral. 69 (10), 5 92 9–5 934 (1995).
   Google Scholar
• Gilbert SC. Virus-like particles as vaccine adjuvants. In: !!!!!!Vaccine Acijuvantr Preparation method and researrh protocols. O'Hagan D (Ed.). Humana Press. Totowa, NJ, USA, 197–210 (2000).
   Google Scholar
• Gilbert SC, Plebanski M, Harris SJ et al. A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol. 15(12), 1280–1284 (1997).
   PubMed Web of Science ®Google Scholar
• KLavinskis LS, Beigmeier LA, Gao L et al. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. hrimund 157(6), 2521–2527 (1996).
   Google Scholar
• Martin SJ, Vyakarnam A, Cheingsong-Popov Ral. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. A/DS7(10), 1315–1323 (1993).
   Google Scholar
• Levine MM, Dougan G. Optimism over vaccines administered via mucosal surfaces. Lancet351, 1375–1376 (1998).
   PubMed Web of Science ®Google Scholar
• O'Hagan D. Microparticles and polymers for the mucosal delivery of vaccines. Ack Drug Deliv Rev 34(2,3), 305–320 (1998).
   Google Scholar
• Vajdy M, O'Hagan DT Micropartides for intranasal immunization. Aclv Drug- Deliv Rev 51(1-3), 127–141 (2001).
   PubMed Web of Science ®Google Scholar
• Challacombe SJ, Rahman D, Jeffery H et al. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. hnmunology76(1), 164–168 (1992).
   Google Scholar
• Challacombe SJ, Rahman D, O'Hagan DT Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine 15 (2), 169–175 (1997).
   PubMed Web of Science ®Google Scholar
• Eldridge JH, Hammond CJ, Meulbroek JA et al. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable miuuspheres target the Peyer's patches. I Control Re1.11, 205–214 (1990).
   Google Scholar
• Cahill ES, O'Hagan DT Illum L et al. Immune responses and protection against Bordete//apertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 13(5), 455–462 (1995).
   PubMed Web of Science ®Google Scholar
• Jones DH, McBride BW Thornton C et al. Orally administered microencapsulated Botyletella pertuffis fimbriae protect mice from B. pettussis respiratory infection. infect. hizmun. 64(2), 489–494 (1996).
   Google Scholar
• Shahin R, Leef M, Eldridge J al. Adjuvanticity and protective immunity elicited by Barietellapertussis antigens encapsulated in poly(DL-lactide-co-glycolide) miul_bpheres. Infect. hnmun. 63(4), 1195–1200 (1995).
   Google Scholar
• Conway MA, Madrigal-Estebas L, McClean S et al. Protection against Botyletella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Thl and Th2 cells. Vaccine 19(15–16), 1940-1950 (2001).
   Google Scholar
• Whittum-Hudson JA, An LL, Saltzman WIVI et al. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamyclia trachomatis infection. Nat. Merl 2(10), 1116–1121 (1996).
   PubMed Web of Science ®Google Scholar
• Allaoui-Attarki K, Pecquet S, Fattal E et al. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) miul_bpheres. hurt [11711711t7. 65(3), 853–857 (1997).
   Google Scholar
• Seo JY, Seong SY, Ahn BY et al. Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in miul_bpheres. Infect. hnmun. 70(3), 1143–1149 (2002).
   Web of Science ®Google Scholar
• Kende M, Yan C, Hewetson J et al. Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric miul_bpheres against aerosol challenge. Vaccine 20(11-12), 1681–1691 (2002).
   PubMed Web of Science ®Google Scholar
• Marx PA, Compans RW, Gettie A et al. Protection against vaginal SW transmission with microencapsulated vaccine. Science 260(5112), 1323–1327 (1993).
   PubMed Web of Science ®Google Scholar
• Tseng J, Komisar JL, Trout RN et al. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres. infect. hizmun. 63(8), 2880–2885 (1995).
   PubMed Web of Science ®Google Scholar
• Ugozzoli M, O'Hagan DT, Ott GS. Intranasal immunization of mice with herpes simplex virus Type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology 93(4), 563–571 (1998).
   Google Scholar
• Jones DH, Corns S, McDonald S et al. Poly (DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 15 (8), 814–817 (1997).
   PubMed Web of Science ®Google Scholar
• Mathiowitz E, Jacob JS, Jong YS et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 386(6623), 410–414 (1997).
   PubMed Web of Science ®Google Scholar
• O'Hagan DT The intestinal uptake of particles and the implications for drug and antigen delivery. Anat. 189 (Pt 3), 477–482 (1996).
   Google Scholar
• Eyles JE, Spiers ID, Williamson ED et al. Tissue distribution of radioactivity following intranasal administration of radioactive microspheres. Phan?. Pharmacol. 53(5), 601–607 (2001).
   Web of Science ®Google Scholar
• Michalek SM, O'Hagan DT, Gould-Fogerite S et al. Antigen delivery systems: nonliving microparticles, liposomes, cochleates and ISCOMS. In: Mucosa' Immunology Second edition. Ogra PL, Mestecky J, Lamm ME, Strober W Bienenstrock J, McGhee JR (Eds). Academic Press San Diego, CA, USA, 759–778 (1999).
   Google Scholar
• Tacket CO, Reid RII, Boedeker EC et al. Enteral immunization and challenge of volunteers given enterotoxigenic E coil CFATII encapsulated in biodegradable microspheres. Vaccine 12 (14), 1270–1274 (1994).
   PubMed Web of Science ®Google Scholar
• Lambert JS, Keefer M, Mulligan MJ et al. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine 19(23–24), 3033–3042 (2001).
   Google Scholar
• Brayden DJ. Oral vaccination in man using antigens in particles: current status. Eur. j Pharm. Sci. 14(3), 183–189 (2001).
   Google Scholar
• Dickinson BL, Clements JD. Dissociation of Escherichia col/heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun. 63(5), 1617–1623 (1995).
   Google Scholar
• Douce G, Turcotte C, Cropley I et al. Mutants of Ercherichia cal/heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Nat/Acad. Acad.Li USA 92(5), 1644–1648 (1995).
   Google Scholar
• Douce G, Fontana M, Pizza M et al. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Irnmun. 65(7), 2821–2828 (1997).
   PubMed Web of Science ®Google Scholar
• Di Tommaso A, Saletti G, Pizza M et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64(3), 974–979 (1996).
   PubMed Web of Science ®Google Scholar
• Giannelli V, Fontana MR, Giuliani MM et al. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop. Infect. Immun. 65(1), 331–334 (1997).
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Del Giudice G, Giannelli V et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia cal/heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. Exp. Med. 187, 1123–1132 (1998).
   Google Scholar
• Marchetti M, Rossi M, Giannelli V et al. Protection against Hlicobacter pyloriinfection in mice by intragastric vaccination with H pylon antigens is achieved using a non-toxic mutant of E cal/heat-labile enterotoxin (LT) as adjuvant. Vaccine 16(1), 33–37 (1998).
   PubMedGoogle Scholar
• Barackman JD, Ott G, Pine S et al. Oral Administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization. Glitz Diagn. Lab. humunol 8(3), 652–657 (2001).
   Google Scholar
• Douce G, Giannelli V, Pizza M et al. Genetically detoxified mutants of heat-labile toxin from Ercherichia cal/ are able to act as oral adjuvants. Infect. [117MUti. 67(9), 4400–4406 (1999).
   Google Scholar
• Rappuoli R, Pizza M, Douce G et al. Structure and mucosal adjuvanticity of cholera and Escherichia cal/heat-labile enterotoxins. humunol Toclay20(11), 493–500 (1999).
   Google Scholar
• Ryan EJ, McNeela E, Murphy GA et al. Mutants of Ercherichia cal/heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Thl and Th2 cells. Infect. humun. 67(12), 6270–6280 (1999).
   Google Scholar
• Jakobsen H, Schulz D, Pizza M et al. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia call heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect. Immun. 67(11), 5892–5897 (1999).
   PubMed Web of Science ®Google Scholar
• O'Hagan D, Goldbeck C, Ugozzoli M et al. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpu, simplex virus Type 2 in guinea-pigs. Vaccine 17(18), 2229–2236 (1999).
   Google Scholar
• Simmons CP, Mastroeni P, Fowler R et al. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. j Immunol 163(12), 6502–6510 (1999).
   PubMed Web of Science ®Google Scholar
• Neidleman JA, Ott G, O'Hagan D (Eds). Mutant heat-labile enterotoxins as adjuvants for CTL induction. Humana Press, Totowa, NJ, USA (2000).
   Google Scholar
• Singh M, Briones M, O'Hagan DT A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. j Contd. Release 70(3), 267–276 (2001).
   PubMed Web of Science ®Google Scholar
• Ugozzoli M, Santos G, Donnelly J et al. Potency of a genetically toxoided mucosal adjuvant derived from the heat-labile enterotoxin of E. call (LTK63) is not adversely affected by the presence of pre-existing immunity to the adjuvant. j Infect. Dir. 183 (2), 351–354 (2001).
   Google Scholar
• Klencke B, Matijevic M, Urban RG etal. Encapsulated plasmid DNA treatmentfor human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin. Cancer Res 8(5), 1028–1037 (2002).
   Google Scholar
• Toda S, Ishii N, Okada E et al. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-y antibody. Immunology92 (1), 111–117 (1997).
   Google Scholar
• Giannasca PJ, Boden JA, Monath TF'. Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins. Infect. hnmun. 65(10), 4288–4298 (1997).
   Google Scholar
• Chen H, Torchilin V, Langer R Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Priam. Res. 13(9), 1378–1383 (1996).
   Google Scholar
• Foster N, Clark MA, Jepson MA et al. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in Ova Vaccine 16(5), 536–541 (1998).
   Google Scholar
• Hussain N, Jani PU, Florence AT Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Phatm. Res. 14(5), 613–618 (1997).
   PubMed Web of Science ®Google Scholar
• Lo D, Hilbush B, Mah S et al. Catching target receptors for drug and vaccine delivery using TOGA gene expression profiling. Ark Drug- Deliv Rev 54(9), 1213–1223 (2002).
   PubMed Web of Science ®Google Scholar
• Agren LC, Ekman L, Lowenadler B et al. Genetically engineered nontoxic vaccine adjuvant that combines B-cell targeting with immunomodulation by cholera toxin Al subunit. Iramunol 158 (8), 3936–3946 (1997).
   PubMed Web of Science ®Google Scholar
• Agren LC, Ekman L, Lowenadler B et al. Adjuvanticity of the cholera toxin Al-based gene fusion protein, CTAl-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. j hnmunol. 162(4), 2432–2440 (1999).
   Google Scholar
• Agren L, Sverremark E, Ekman L et al. The ADP-ribosylating CTAl-DD adjuvant enhances T-cell-dependent and independent responses by direct action on B-cells involving anti-apoptotic Bc1-2- and germinal center-promoting effects. I humunol 164(12), 6276–6286 (2000).
   Google Scholar
• Goletz TJ, KlimpelKR, Arora N et al. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Proc. Natl Acad. Sci. USA 94(22), 12059–12064 (1997).
   Google Scholar